Colesevelam – a bile acid sequestrant for treating hypercholesterolemia and improving hyperglycemia

References

• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. 2017 Aug 21;38(32):2459–2472.
   PubMed Web of Science ®Google Scholar
• Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009 Nov 11;302(18):1993–2000.
   PubMed Web of Science ®Google Scholar
• Marston NA, Giugliano RP, Im K, et al. Association between triglyceride lowering and reduction of cardiovascular Risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials. Circulation. 2019 Oct 15;140(16):1308–1317.
   PubMed Web of Science ®Google Scholar
• Chait A, Ginsberg HN, Vaisar T, et al. Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease. Diabetes. 2020 Apr;69(4):508–516.
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 Aug 10;366(9493):1267–1278.
   PubMed Web of Science ®Google Scholar
• Manghat P, Wierzbicki AS. Colesevelam - a specifically engineered bile acid sequestrant. Future Lipidology. 2008;3(3):237–255.
   Web of Science ®Google Scholar
• Alder M, Bavishi A, Zumpf K, et al. A Meta-analysis assessing additional LDL-C reduction from addition of a bile acid sequestrant to statin therapy. Am J Med. 2020 Nov;133(11):1322–1327.
   PubMed Web of Science ®Google Scholar
• Wang N, Fulcher J, Abeysuriya N, et al. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants. Lancet Diabetes Endocrinol. 2020 Jan;8(1):36–49.
   PubMed Web of Science ®Google Scholar
• Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. ArteriosclerThrombVascBiol. 1999 2;19(2):187–195.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015 Jun 18;372(25):2387–2397.
   PubMed Web of Science ®Google Scholar
• Khan SU, Talluri S, Riaz H, et al. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes. Eur J Preventive Cardiol. 2018 Jan 1:2047487318766612.
   Web of Science ®Google Scholar
• The Lipid Research Clinics (LRC) coronary primary prevention trial investigators. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984 Jan 20;251(3):351–364.
   PubMed Web of Science ®Google Scholar
• Brunetti L, DeSantis EH. Patient tolerance and acceptance of colesevelam hydrochloride: focus on type-2 diabetes mellitus. P T. 2015 Jan;40(1):62–67. .
   PubMedGoogle Scholar
• Insull WsJr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. SouthMedJ. 2006 3;99(3):257–273.
   Google Scholar
• Zhang B, Kuipers F, de Boer JF, et al. Modulation of bile acid metabolism to improve plasma lipid and lipoprotein profiles. J Clin Med. 2021 Dec 21;11(1):4.
   PubMed Web of Science ®Google Scholar
• Zema MJ. Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action. Core Evid. 2012;7:61–75.
   PubMedGoogle Scholar
• Donovan JM, Von BK, Setchell KD, et al. Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. DigDisSci. 2005 7;50(7):1232–1238.
   Google Scholar
• Colesevelam. GT 31104, CholestaGel. Drugs RD. 1999 6;1(6):479–480.
   PubMedGoogle Scholar
• Braunlin W, Zhorov E, Smisek D, et al. Invitro comparison of bile acid binding to colesevelam HCl and other bile acid sequestrants. Polym Preprints. 2000;41(1):708–709.
   Google Scholar
• Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. ExpertOpinPharmacother. 2003 5;4(5):779–790. .
   Web of Science ®Google Scholar
• Aldridge MA, Ito MK. Colesevelam hydrochloride: a novel bile acid-binding resin. AnnPharmacother. 2001 7;35(7–8):898–907.
   Web of Science ®Google Scholar
• Brown DD, Schmid J, Long RA, et al. A steady-state evaluation of the effects of propantheline bromide and cholestyramine on the bioavailability of digoxin when administered as tablets or capsules. J Clin Pharmacol. 1985 7;25(5):360–364.
   PubMed Web of Science ®Google Scholar
• Donovan JM, Stypinski D, Stiles MR, et al. Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. CardiovascDrugs Ther. 2000 12;14(6):681–690.
   Google Scholar
• British National Formulary. Colesevelam hydrochloride London, United Kingdom: National Institute for Helath and Clinical Excellence; 2022. [cited 2022 Jan 6]. Available from: https://bnf.nice.org.uk/drugs/colesevelam-hydrochloride/
   Google Scholar
• Canadian Drug Expert Committee (CDEC). Common drug review: final CDEC recommendation: colesevelam hydrochloride (Lodalis – valeant Canada LP) Ottawa: Canada: Canadian Agency for Drugs and Technologies in Health; 2012 [updated 19 Dec 2012; cited 2022 Jan 19]. Final CDEC Recommendation - Lodalis - CADTH Available from: https://www.cadth.ca›default›files›cdr›complete
   Google Scholar
• Galescu OA. Clinical review NDA 210895 Welchol (colesevelam hydrochloride) Washington DC USA: food and drug administration. 2017. [updated 08 Aug 2018; cited 2022 Jan 6]. Clinical Review Ovidiu A. Galescu, MD NDA 210895 Welchol Available from: https://www.fda.gov›media›download
   Google Scholar
• Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. ArchInternMed. 1999 13 Sep;159(16):1893–1900.
   Google Scholar
• Insull WsJr., Toth P, Mullican W, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo ClinProc. 2001 10;76(10):971–982.
   PubMed Web of Science ®Google Scholar
• Ye X, Qian C, Liu J, et al. Lower risk of major cardiovascular events associated with adherence to colesevelam HCI. Pharmacotherapy. 2013 Oct;33(10):1062–1070.
   PubMed Web of Science ®Google Scholar
• Romanelli RJ, Leahy A, Jukes T, et al. Multivariate analysis of factors associated with persistent colesevelam treatment among patients with hypercholesterolemia. Ann Pharmacother. 2013 Oct;47(10):1247–1252.
   PubMed Web of Science ®Google Scholar
• Davidson MH, Toth P, Weiss S, et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. ClinCardiol. 2001 6;24(6):467–474.
   Web of Science ®Google Scholar
• Hunninghake D, Insull WsJr., Toth P, et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis. 2001 10;158(2):407–416.
   PubMed Web of Science ®Google Scholar
• Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. 2001 1 Apr;110(5):352–360.
   PubMed Web of Science ®Google Scholar
• Schmidt DR, Holmstrom SR, Fon TK, et al. Regulation of bile acid synthesis by fat-soluble vitamins A and D. J Biol Chem. 2010 7 May;285(19):14486–14494.
   PubMed Web of Science ®Google Scholar
• Jacobson TA, Armani A, McKenney JM, et al. Safety considerations with gastrointestinally active lipid-lowering drugs. AmJ Cardiol. 2007 19 Mar;99(6A):47C–55C.
   PubMed Web of Science ®Google Scholar
• Bays HE, Davidson M, Jones MR, et al. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. AmJ Cardiol. 2006 15 Apr;97(8):1198–1205.
   PubMed Web of Science ®Google Scholar
• Reddy KJ, Singh M, Batsell RR, et al. Efficacy of combination drug pulse therapy in maintaining lipid levels in patients intolerant of daily statin use. J ClinHypertens(Greenwich). 2009 12;11(12):766–768.
   PubMed Web of Science ®Google Scholar
• Xydakis AM, Guyton JR, Chiou P, et al. Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. AmJ Cardiol. 2004 15 Sep;94(6):795–797.
   PubMed Web of Science ®Google Scholar
• Knopp RH, Tsunehara C, Retzlaff BM, et al. Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study. Metabolism. 2006 12;55(12):1697–1703.
   PubMed Web of Science ®Google Scholar
• Bays H, Rhyne J, Abby S, et al. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. CurrMedResOpin. 2006 11;22(11):2191–2200.
   Google Scholar
• Rivers SM, Kane MP, Busch RS, et al. Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. EndocrPract. 2007 1;13(1):11–16.
   Google Scholar
• McKenney J, Jones M, Abby S. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. CurrMedResOpin. 2005 9;21(9):1403–1412.
   Google Scholar
• Huijgen R, Abbink EJ, Bruckert E, et al. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. ClinTher. 2010 4;32(4):615–625.
   Google Scholar
• Moore AB, Phan BA, Challender C, et al. Effects of adding extended-release niacin and colesevelam to statin therapy on lipid levels in subjects with atherosclerotic disease. J ClinLipidol. 2007;1(6):620–625.
   PubMed Web of Science ®Google Scholar
• Bays H, Jones PH. Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors. VascHealth Risk Manag. 2007;3(5):733–742.
   PubMedGoogle Scholar
• van Nierop FS, Scheltema MJ, Eggink HM, et al. Clinical relevance of the bile acid receptor TGR5 in metabolism. Lancet Diabetes Endocrinol. 2017 Mar;5(3):224–233.
   PubMed Web of Science ®Google Scholar
• Claudel T, Staels B, Kuipers F. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. ArteriosclerThrombVascBiol. 2005 10;25(10):2020–2030.
   PubMed Web of Science ®Google Scholar
• Staels B, Fonseca VA. Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration.Diabetes Care. 2009 11;32(suppl_2):S237–S245.
   PubMedGoogle Scholar
• Herrema H, Meer M, van Dijk TH, et al. Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor- and liver X receptor alpha-controlled metabolic pathways in mice. Hepatology. 2010 3;51(3):806–816.
   PubMed Web of Science ®Google Scholar
• Stayrook KR, Bramlett KS, Savkur RS, et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology. 2005 Mar;146(3):984–991.
   PubMed Web of Science ®Google Scholar
• Zhou H, Hylemon PB. Bile acids are nutrient signaling hormones. Steroids. 2014 Aug;86:62–68.
   PubMed Web of Science ®Google Scholar
• Bays H, Stein EA. Pharmacotherapy for dyslipidaemia–current therapies and future agents. Expert Opin Pharmacother. 2003 Nov;4(11):1901–1938.
   PubMed Web of Science ®Google Scholar
• Sedgeman LR, Beysen C, Allen RM, et al. Intestinal bile acid sequestration improves glucose control by stimulating hepatic miR-182-5p in type 2 diabetes. Am J Physiol Gastrointest Liver Physiol. 2018 Nov 1;315(5):G810–G823.
   PubMed Web of Science ®Google Scholar
• Trabelsi MS, Lestavel S, Staels B, et al. Intestinal bile acid receptors are key regulators of glucose homeostasis. Proc Nutr Soc. 2017 Aug;76(3):192–202.
   PubMed Web of Science ®Google Scholar
• Smushkin G, Sathananthan M, Piccinini F, et al. The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes. Diabetes. 2013 Apr;62(4):1094–1101.
   PubMed Web of Science ®Google Scholar
• Hansen M, Scheltema MJ, Sonne DP, et al. Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion. Diabetes Obes Metab. 2016 Jun;18(6):571–580.
   PubMed Web of Science ®Google Scholar
• Zieve FJ, Kalin MF, Schwartz SL, et al. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. ClinTher. 2007 1;29(1):74–83.
   Google Scholar
• Bays HE, Goldberg RB, Truitt KE, et al. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. ArchInternMed. 2008 Oct 13;168(18):1975–1983.
   Google Scholar
• Fonseca VA, Rosenstock J, Wang AC, et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008 8;31(8):1479–1484.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Truitt KE, Baz-Hecht M, et al. Efficacy and safety of colesevelam in combination with pioglitazone in patients with type 2 diabetes mellitus. Horm Metab Res. 2014 Dec;46(13):943–949.
   PubMed Web of Science ®Google Scholar
• Rigby SP, Handelsman Y, Lai YL, et al. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. EndocrPract. 2010 1;16(1):53–63.
   Google Scholar
• Goldberg RB, Fonseca VA, Truitt KE, et al. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. ArchInternMed. 2008 28 Jul;168(14):1531–1540.
   Google Scholar
• Rosenstock J, Fonseca VA, Garvey WT, et al. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract. 2010 Jul-Aug;16(4):629–640.
   PubMed Web of Science ®Google Scholar
• Schwartz SL, Lai YL, Xu J, et al. The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a Pilot Study. Metab SyndrRelat Disord. 2010 Aug 1;8(2):179–188.
   PubMed Web of Science ®Google Scholar
• Beysen C, Murphy EJ, Deines K, et al. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia. 2012 Feb;55(2):432–442.
   PubMed Web of Science ®Google Scholar
• Henry RR, Aroda VR, Mudaliar S, et al. Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012 Jan;14(1):40–46.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Rigby SP, Ford DM, et al. The glucose and lipid effects of colesevelam as monotherapy in drug-naive type 2 diabetes. Horm Metab Res. 2014 May;46(5):348–353.
   PubMed Web of Science ®Google Scholar
• Hansen M, Sonne DP, Mikkelsen KH, et al. Bile acid sequestrants for glycemic control in patients with type 2 diabetes: a systematic review with meta-analysis of randomized controlled trials. J Diabetes Complications. 2017 May;31(5):918–927.
   PubMed Web of Science ®Google Scholar
• Garg SK, Ritchie PJ, Moser EG, et al. Effects of colesevelam on LDL-C, A1c and GLP-1 levels in patients with type 1 diabetes: a pilot randomized double-blind trial. Diabetes Obes Metab. 2011 Feb;13(2):137–143.
   PubMed Web of Science ®Google Scholar
• Bajaj HS, Brown RE, Jiandani D, et al. Goal achievement of HbA1c and LDL-cholesterol in a randomized trial comparing colesevelam with ezetimibe: GOAL-RCT. Diabetes Obes Metab. 2020 Oct;22(10):1722–1728.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the american college of cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2018 2019 Jun 18;139(25):e1082–e1143.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019 Aug 31;40(32):2700–2709.
   PubMedGoogle Scholar
• Wierzbicki AS, Humphries SE, Minhas R. Familial hypercholesterolaemia: summary of NICE guidance. BMJ. 2008;337(2):a1095.
   PubMedGoogle Scholar
• The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975 27 Jan;231(4):360–381.
   PubMed Web of Science ®Google Scholar
• Collaborative Group HPSTHRIVE, Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014 Jul 17;371(3):203–212.
   PubMed Web of Science ®Google Scholar
• Saha SA, Kizhakepunnur LG, Bahekar A, et al. The role of fibrates in the prevention of cardiovascular disease–a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. AmHeart J. 2007 11;154(5):943–953.
   PubMed Web of Science ®Google Scholar
• Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010 29 May;375(9729):1875–1884.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010 29 Apr;362(17):1563–1574.
   PubMed Web of Science ®Google Scholar
• Fei Y, Tsoi MF, Cheung BMY. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. Cardiovasc Diabetol. 2019 Aug 28;18(1):112.
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010 27 Feb;375(9716):735–742.
   PubMed Web of Science ®Google Scholar
• Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016 Nov 19;388(10059):2532–2561.
   PubMed Web of Science ®Google Scholar
• Khan SU, Rahman H, Okunrintemi V, et al. Association of lowering low-density lipoprotein cholesterol with contemporary Lipid-lowering therapies and risk of diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc. 2019 Apr 2;8(7):e011581.
   PubMed Web of Science ®Google Scholar
• Schmidt AF, Swerdlow DI, Holmes MV, et al. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol. 2017 Feb;5(2):97–105.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the Fourier randomised controlled trial. Lancet Diabetes Endocrinol. 2017 Dec;5(12):941–950.
   PubMed Web of Science ®Google Scholar
• Vogt A, Kassner U, Hostalek U, et al. Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study. CurrMed ResOpin. 2006 2;22(2):417–425.
   PubMed Web of Science ®Google Scholar
• Flory JH, Ellenberg S, Szapary PO, et al. Antidiabetic action of bezafibrate in a large observational database. Diabetes Care. 2009 4;32(4):547–551.
   PubMed Web of Science ®Google Scholar
• Vahedian-Azimi A, Bianconi V, Makvandi S, et al. A systematic review and meta-analysis on the effects of statins on pregnancy outcomes. Atherosclerosis. 2021 Nov;336:1–11.
   PubMed Web of Science ®Google Scholar
• Wah-Suarez MI, Danford CJ, Patwardhan VR, et al. Hyperlipidaemia in primary biliary cholangitis: treatment, safety and efficacy. Frontline Gastroenterol. 2019 Oct;10(4):401–408.
   PubMed Web of Science ®Google Scholar
• Wedlake L, Thomas K, Lalji A, et al. Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: a retrospective chart review and patient questionnaire. ClinTher. 2009 11;31(11):2549–2558.
   Google Scholar
• Bergasa NV. Pruritus and fatigue in primary biliary cirrhosis. Clin Liver Dis. 2003 Nov;7(4):879–900.
   PubMedGoogle Scholar
• Karhus ML, Bronden A, Lyng Forman J, et al. Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption. BMJ Open. 2021 Feb 8;11(2):e044711.
   PubMed Web of Science ®Google Scholar